Opportunity Information: Apply for RFA CE 10 002
Apply for RFA CE 10 002
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Unintentional Poisoning from Prescription Drug Overdoses in Adults (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.136 Injury Prevention and Control Research and State and Community Based Programs.
- This funding opportunity was created on Oct 28, 2009 and posted on Oct 28, 2009.
- Applicants must submit their applications by Jan 19, 2010 Letter of Intent Receipt Date December 21, 2009 Application Submission Receipt Date January 19, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $350,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible Organizations Public nonprofit organizations private nonprofit organizations for profit organizations small, minority, and women owned businesses universities colleges research institutions hospitals community based organizations faith based organizations federally recognized or state recognized American Indian/Alaska Native tribal governments American Indian/Alaska Native tribally designated organizations Alaska Native health corporations urban Indian health organizations tribal epidemiology centers state and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) and political subdivisions of states (in consultation with states.) A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If you are applying as a bona fide agent of a state or local government, you must provide required documentation from the state or local government as documentation of your status. Attach this documentation behind the first page of your application form or for electronic applications, use a PDF file and attach as Other Documents and label as appropriate.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Unintentional Poisoning from Prescription Drug Overdoses in Adults (R21) opportunity (Funding Opportunity Number RFA-CE-10-002) was a CDC discretionary grant aimed at strengthening the scientific evidence base for preventing unintentional poisonings and overdoses involving prescription drugs among adolescents and adults ages 15 to 64. The announcement focused on exploratory and developmental research under the NIH-style R21 mechanism, meaning it was geared toward early-stage, innovative studies that test new ideas, generate preliminary data, and evaluate novel prevention approaches that could later be expanded into larger, more definitive research efforts. The overall intent was to support work aligned with the National Center for Injury Prevention and Control (NCIPC) research agenda priorities for unintentional poisoning, while also fitting with the FDA Center for Drug Evaluation and Research (CDER) mission around pharmaceutical safety and the broader Safe Use initiative, which emphasizes improving the safety of marketed medications through partnerships with the health care community.
At its core, the grant called for projects that move beyond describing the problem and instead explore practical ways to prevent overdose events and deaths tied to prescription medications. It encouraged applicants to examine new strategies, interventions, and policy or systems-level approaches that could reduce unintentional overdoses, improve safer prescribing and dispensing, reduce risky medication use behaviors, and strengthen prevention across clinical, community, and public health settings. Because it explicitly sought to engage professionals across many disciplines, it signaled interest in multi-sector and multi-method research, including epidemiology and surveillance, community and clinical medicine, pharmacology, biostatistics, behavioral and social sciences, justice and legal perspectives, public policy, and public health law. In practice, that interdisciplinary framing suggests the CDC wanted applications that could connect the medical side of prescription drug use with real-world patterns of misuse, diversion, or unsafe combinations, and with the policy and health system environments that shape risk.
The award was relatively small and targeted: the CDC expected to make about two awards, with an estimated total funding amount of $350,000 and an award ceiling of $350,000 (with no stated minimum award floor). There was no cost-sharing or matching requirement. The funding activity category was health, under CFDA 93.136 (Injury Prevention and Control Research and State and Community Based Programs). The timeline indicates the opportunity was posted on October 28, 2009, with a letter of intent due December 21, 2009, and full applications due January 19, 2010. The archive date was February 18, 2010, indicating it was a time-limited competition rather than an open, continuously available program.
Eligibility was intentionally broad and included a wide range of organizational types: public and private nonprofit organizations, for-profit organizations (including small businesses and minority- and women-owned businesses), universities and colleges, research institutions, hospitals, community-based and faith-based organizations, and multiple levels of government. It also explicitly included federally or state-recognized American Indian and Alaska Native tribal governments and tribally affiliated entities such as tribal epidemiology centers, Alaska Native health corporations, urban Indian health organizations, and tribally designated organizations. State and local governments and their bona fide agents were eligible as well, including U.S. territories and freely associated states listed in the announcement; entities applying as bona fide agents needed to provide documentation from the relevant state or local government.
In summary, this FOA was designed to catalyze early, innovative research that could lead to more effective prevention of unintentional prescription drug overdose among people ages 15 to 64, emphasizing novel approaches, interdisciplinary collaboration, and alignment with national injury prevention priorities and pharmaceutical safety goals. For applicants, the key signal was that the CDC was looking for creative, testable prevention ideas with potential for real-world impact, rather than large, long-term trials or purely descriptive studies. For questions or technical issues accessing the announcement, the listed contact was the CDC Procurement and Grants Office Technical Information Management line at 770-488-2700.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled Unintentional Poisoning from Prescription Drug Overdoses in Adults (R21).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-CE-10-002.
Which federal agency offered this grant?
This was a CDC discretionary grant, aligned with priorities of the National Center for Injury Prevention and Control (NCIPC) and also relevant to the FDA Center for Drug Evaluation and Research (CDER) mission related to medication safety and the Safe Use initiative.
What problem area was the grant intended to address?
The grant aimed to strengthen the scientific evidence base for preventing unintentional poisonings and overdoses involving prescription drugs, with a focus on prevention rather than problem description.
Who was the intended population for the research focus?
The announcement targeted adolescents and adults ages 15 to 64.
What type of research mechanism was used (R21)?
The funding used an NIH-style R21 mechanism, intended for exploratory and developmental research. This means the FOA was geared toward early-stage, innovative studies that test new ideas, generate preliminary data, and evaluate novel prevention approaches that could later be expanded into larger research efforts.
What kinds of projects was CDC looking for?
The FOA emphasized projects that move beyond describing overdose trends and instead explore practical, testable ways to prevent overdose events and deaths tied to prescription medications. It encouraged examination of new strategies, interventions, and policy or systems-level approaches that could reduce unintentional overdoses.
What prevention topics or approaches were encouraged?
Based on the announcement summary, encouraged directions included work that could:
- Reduce unintentional overdoses and overdose deaths involving prescription medications
- Improve safer prescribing and dispensing practices
- Reduce risky medication use behaviors
- Strengthen prevention across clinical, community, and public health settings
- Evaluate interventions or approaches that could later scale into larger studies
- Consider policy and systems-level strategies that influence overdose risk
Was the grant focused on descriptive studies, or on prevention solutions?
The FOA specifically signaled interest in work that moves beyond describing the problem and instead tests or evaluates prevention-oriented strategies and interventions.
What disciplines were relevant for applicants?
The announcement indicated interest in multi-sector and multi-method research, with examples including:
- Epidemiology and surveillance
- Community and clinical medicine
- Pharmacology
- Biostatistics
- Behavioral and social sciences
- Justice and legal perspectives
- Public policy
- Public health law
Did the FOA encourage interdisciplinary or cross-sector collaboration?
Yes. The opportunity explicitly signaled interest in interdisciplinary work connecting clinical and pharmaceutical safety considerations with real-world patterns of unsafe use and with the policy and health system environments that shape overdose risk.
How many awards did CDC expect to make?
The CDC expected to make about two awards.
How much total funding was estimated for the opportunity?
The estimated total funding amount was $350,000.
What was the maximum award amount (award ceiling)?
The award ceiling was $350,000.
Was there a minimum award amount?
No minimum award floor was stated in the provided information.
Was cost sharing or matching required?
No. There was no cost-sharing or matching requirement.
What was the funding activity category?
The funding activity category was Health.
What CFDA number was associated with this opportunity?
The CFDA number listed was 93.136, described as Injury Prevention and Control Research and State and Community Based Programs.
When was the opportunity posted?
The opportunity was posted on October 28, 2009.
Was a letter of intent required, and when was it due?
A letter of intent (LOI) was part of the timeline, due on December 21, 2009.
When were full applications due?
Full applications were due on January 19, 2010.
Is this opportunity still open?
No. The archive date was February 18, 2010, indicating it was a time-limited competition rather than an open, continuously available program.
Who was eligible to apply?
Eligibility was broad and included a wide range of organization types, including:
- Public and private nonprofit organizations
- For-profit organizations (including small businesses and minority- and women-owned businesses)
- Universities and colleges
- Research institutions
- Hospitals
- Community-based and faith-based organizations
- State, local, and certain territorial governments and their eligible entities
- Federally or state-recognized American Indian and Alaska Native tribal governments and tribally affiliated entities
Which tribal and tribally affiliated entities were explicitly included?
The announcement explicitly included federally or state-recognized American Indian and Alaska Native tribal governments and tribally affiliated entities such as:
- Tribal epidemiology centers
- Alaska Native health corporations
- Urban Indian health organizations
- Tribally designated organizations
Were U.S. territories or freely associated states included?
Yes. The information notes that eligibility included U.S. territories and freely associated states listed in the announcement.
What is a "bona fide agent" and what documentation was required?
State and local governments and their bona fide agents were eligible. Entities applying as bona fide agents needed to provide documentation from the relevant state or local government.
What was the overall intent of the FOA?
The overall intent was to catalyze early, innovative research that could lead to more effective prevention of unintentional prescription drug overdose among people ages 15 to 64, emphasizing novel approaches, interdisciplinary collaboration, and alignment with national injury prevention priorities and pharmaceutical safety goals.
How did the FOA relate to NCIPC priorities and FDA CDER goals?
The FOA aimed to support work aligned with the NCIPC research agenda priorities for unintentional poisoning, while also fitting with the FDA CDER mission around pharmaceutical safety and the broader Safe Use initiative, which emphasizes improving the safety of marketed medications through partnerships with the health care community.
Who was the contact for questions or technical issues accessing the announcement?
The listed contact was the CDC Procurement and Grants Office Technical Information Management line at 770-488-2700.
Browse more opportunities from the same category: Health
Next opportunity: Strengthening Women s Organizations and Political Representation in the Middle East and North Africa
Previous opportunity: Development and Characterization of Animal Models for Aging Research (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CE 10 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CE 10 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development and Characterization of Animal Models for Aging Research (R21) Apply for PA 10 015 Funding Number: PA 10 015 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NEI Clinical Study Planning Grant Program (R34) Apply for PAR 10 017 Funding Number: PAR 10 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technologies for Image Guided Interventions (R01) Apply for RFA EB 09 002 Funding Number: RFA EB 09 002 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| FY10 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Central Pennsylvania). Apply for PA FPH 10 008 Funding Number: PA FPH 10 008 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,959,200 |
| FY10 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Michigan and Illinois) Apply for PA FPH 10 009 Funding Number: PA FPH 10 009 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $8,308,700 |
| Nurse Education, Practice and Retention Apply for HRSA 10 046 Funding Number: HRSA 10 046 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Patient Oriented Research Career Development Award in Aging (K23) Apply for RFA AG 10 011 Funding Number: RFA AG 10 011 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Partnerships in Implementing Patient Safety II (R18) Apply for PAR 10 022 Funding Number: PAR 10 022 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $300,000 |
| Paul B. Beeson Clinical Scientist Development Award in Aging (K08) Apply for RFA AG 10 010 Funding Number: RFA AG 10 010 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| APS Support for International Family Planning Organizations (SIFPO) Apply for M OAA GH POP 10 001 Funding Number: M OAA GH POP 10 001 Agency: Agency for International Development Category: Health Funding Amount: $40,000,000 |
| Advanced Education Nursing Traineeship Apply for HRSA 10 048 Funding Number: HRSA 10 048 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Nurse Anesthetist Traineeships Apply for HRSA 10 050 Funding Number: HRSA 10 050 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Leveraging Existing Health care Networks to Transform Effectiveness Research (U19) Apply for RFA MH 10 030 Funding Number: RFA MH 10 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Centers for Biomedical Computing (U54) Apply for RFA RM 09 002 Funding Number: RFA RM 09 002 Agency: National Institutes of Health Category: Health Funding Amount: $2,330,000 |
| NIBIB Quantum Projects Implementation Phase II (U01) Apply for RFA EB 09 003 Funding Number: RFA EB 09 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Special Diabetes Program for Indians, Cycle II Apply for HHS 2010 IHS 0002 Funding Number: HHS 2010 IHS 0002 Agency: Indian Health Service Category: Health Funding Amount: $1,000,000 |
| Seeding National Mentoring Networks to Enhance Diversity of the Mental Health Research Workforce (U24) Apply for RFA MH 10 050 Funding Number: RFA MH 10 050 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Effectiveness Research on Smoking Cessation in Hospitalized Patients Research Coordinating Unit (U01) Apply for RFA HL 10 025 Funding Number: RFA HL 10 025 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Projects to Deliver Peer to Peer Recovery Support Services Apply for TI 10 010 Funding Number: TI 10 010 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $350,000 |
| SCALE UP OF INDOOR RESIDUAL SPRAYING (IRS) IN TANZANIA Apply for USAID TANZANIA 10 002 RFA Funding Number: USAID TANZANIA 10 002 RFA Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $130,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CE 10 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.